APPENDIX 1

Serum biomarkers' analysis techniques

Serum albumin was analyzed by bromcresol green colorimetric assay (Cobas C701; Roche Diagnostic, Indianapolis, IN, USA), CRP by immunoturbidimetry (Cobas C502; Roche Diagnostic, Indianapolis, IN, USA), creatinine and glucose by enzymatic assay (Cobas C701; Roche Diagnostic, Indianapolis, IN, USA), total IGF-1 by chemiluminescent immunometric assay (Immulite 2000; Siemens Healthcare Diagnostic) while Vitamin D 25-OH was analyzed by the electrochemiluminescence immunoassay (ECLIA; Cobas C602; Roche Diagnostic, Indianapolis, IN, USA).

Serum biomarkers' coefficients of variation

Albumin

2.5% for a concentration of 43 g/L 3.2% for a concentration of 30 g/L

Creatinine

2.5% for a concentration of 83 μ mol/L 1.6% for a concentration of 630 μ mol/L

CRP

1.5% for a concentration of 6 mg/L 3.0% for a concentration of 30 mg/L

Vitamin D

8.1% for a concentration of 45 nmol/L 3.5% for a concentration of 90 nmol/L

Glucose

1.5% for a concentration of 3.3 mmol/L 1.3% for a concentration of 19.0 mmol/L

IGF-1

7.5% for a concentration of 34 μ g/L 3.6% for a concentration of 93 μ g/L 3.5% for a concentration of 571 μ g/

APPENDIX 2

Biomarkers' clinical threshold values and baseline distribution of serum biomarkers

Albumin (g/L)

Low: < 35 Normal: 35 - 50 High: > 50

Normal values: normal or high (≥ 35)

At risk values: low (< 35)

Creatinine (µmol/L)

Low: male < 55; female < 45

Normal: male: 55 - 105, female: 45 - 85

High: male > 105; female > 85

Normal values: normal or low (male ≤ 105 ; female ≤ 85)

At risk values: high (male > 105; female > 85)

CRP (mg/L)

Normal: < 10High: ≥ 10

Normal values: < 10At risk values: ≥ 10

Vitamin D 25-OH (nmol/L)

Low: < 50 Normal: 50 – 125

High: > 125

Normal values: 50 - 125

At risk values: low or high (< 50 or > 125)

Glucose (mmol/L)

Normal: ≤ 6.0 High: > 6.0

Normal values: ≤ 6.0 High values: > 6.0

IGF-1 (µg/L)

Low: < 50 Normal: 50 - 270 High: > 270

Normal values: normal or high (≥ 50)

At risk values: low (< 50)

The threshold clinical values used for each biomarker are those used at the CHU de Québec and are generally clinically recognized as "normal", "low" or "high" values, reflecting a normal or impaired physiological state.

Distribution of serum biomarkers

| | N (%) | |
|---|------------------|--|
| Albumin (g/L) | | |
| Low: < 35 | 4 (2.1) | |
| Normal: 35 – 50 | 179 (94.2) | |
| High: > 50 | 7 (3.7) | |
| Mean value ^a | 43.6 ± 4.2 | |
| Creatinine (µmol/L) | | |
| Low: male < 55; female < 45 | 1 (0.5) | |
| Normal: male: 55 - 105, female: 45 – 85 | 144 (75.8) | |
| High: male > 105; female > 85 | 45 (23.7) | |
| Mean value male ^a | 94.2 ± 24.5 | |
| Mean value female ^a | 74.0 ± 20.3 | |
| Mean value total ^a | 84.7 ± 24.7 | |
| CRP (mg/L) | | |
| Normal: < 10 | 149 (78.4) | |
| High: \geq 10 | 41 (21.6) | |
| Mean value ^b | 10.8 (8.3-14.0) | |
| Vitamin D (nmol/L) | | |
| Low: < 50 | 46 (24.3) | |
| Normal: 50 – 125 | 122 (64.6) | |
| High: > 125 | 21 (11.1) | |
| Mean value ^a | 80.5 ± 38.9 | |
| Glucose (mmol/L) | | |
| Normal: ≤ 6.0 | 99 (52.7) | |
| High: > 6.0 | 89 (47.3) | |
| Mean value ^a | 6.8 ± 2.3 | |
| IGF-1 (μ g/L) | | |
| Low: < 50 | 12 (6.5) | |
| Normal: 50 – 270 | 172 (93.0) | |
| High: > 270 | 1 (0.5) | |
| Mean value ^a | 129.7 ± 56.0 | |

n = 190 patients with baseline serum biomarkers

aResults are present as means ± standard deviation

bResults for CRP are presented as geometric mean and 95% confidence interval

APPENDIX 3

Overall prospective 3-months functional decline and mobility characteristics^a

| Indicators | Baseline N*(%) | 3-months N*(%) | p-value |
|---|-------------------|-------------------|---------|
| Functional status (OARS) | 21 (70) | 11 (70) | |
| No decline | | 137 (81.6) | NA |
| \downarrow OARS \geq 2 pts | | 16 (9.5) | NA |
| \downarrow OARS-ADL \geq 1 pt | | 28 (16.7) | NA |
| Total score | 28±1 | 27±2 | 0.02 |
| Mobility characteristics | | | |
| OARS - IADL (< 14/14) | 40 (23.8) | 34 (20.4) | NS |
| Slow walkers (Timed-Up-Go ≥ 15 seconds) | 16 (40.0) | 6 (15.0) | 0.0075 |
| Occasional use of a walking aid | 22 (15.1) | 29 (19.9) | 0.0522 |
| Less than 5 outings/week | 37 (25.0) | 48 (32.4) | 0.0782 |
| Short FES-1 (VAS < 9.8/10) | 63 (41.7) | 76 (50.3) | 0.0579 |

^aAnalysis performed only with patients who had baseline and 3-months values.

OARS: Older American Adult resources and Service scale

Short FES-1: Short Falls Efficacy Scale (fear of falling)